EGFR and colorectal carcinoma: Then the patients with rapid distant metastasis seemed more likely to be initial resistant to anti-EGFR MoAbs, because KRAS mutation maintained throughout the CRC development, progression and metastasis, with a high (95%) concordance presenting at the primary and related metastatic sites [26]–[27].